ArticleCancer chemotherapy and pharmacology2020

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.

L H Mammatas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.